Clinical Trial Update: Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial update for therapy in untreated DLBCL patients across risk groups; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Non-hodgkin Lymphoma

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Non-Hodgkin's Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2022-06-21